[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版). 肝脏,2015, 20: 915-932.
[2] Bonino F, Brunetto MR.Occult hepatitis B virus (HBV) infections: Hepatitis B surface antigen (HBsAg) negative and primary occult. Curr Hepatitis Rep,2013,12:112-118.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57:167-185.
[4] Raimondo G,Caccamo G,Filomia R,et al. Occult HBV infection. Semin Immunopathol,2013,35:39-52.
[5] Pollicino T,Raimondo G.Occult hepatitis B infection. J Hepatol,2014,61:688-689.
[6] 马源,张玲荣,王博,等.不明原因肝病患者中隐匿性HBV感染的研究.中国医疗前沿,2011,6:5-6.
[7] Jang JW, Kim YW, Lee SW, et al.Reactivation of Hepatitis B Virus in HBsAg-Negative Patients with Hepatocellular- Carcinoma. PLoS ONE, 2015,10:1-12.
[8] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57:167-185.
[9] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).中国肝脏病杂志(电子版),2015,7:1-18.
[10] 张黄醒,张振华,张礼周,等.干扰素治疗慢性乙型肝炎出现HBsAg/抗-HBs血清转换后病情复发.实用肝脏病杂志,2013,16:128-130.
[11] Minuk GY, Sun DF, Uhanova J, et al.Occult hepatitis B virus infection in a North American community-based population. J Hepatol,2005,42:480-485.
[12] Konstantinou D,Deutsch M.The spectrum of HBV/HCV coinfection: epidemiology,clinical,characteristics,viralinter- actions and management. Annals of Gastroenterology,2015,28:221-228.
[13] Yuan Q, Wu CX,Liu FF,et al. Clinical analysis of Occult hepatitis B virus infection in 110 HBsAg- negative patients.Med J Chin PLA,2015,40:133-136.
[14] Martin P, Lau DT, Nguyen MH, et al. A treatmen algorithm for the management of chronic hepatitis B virus infection in the united states: 2015 update. Clinical Gastroenterology an Hepatology, 2015, 13:2071-2087.
[15] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015.
[16] Zhang Z,Zhang L,Dai Y,et al.Occult hepatitis B virus infection: influence of S protein variants. Virology Journal,2016,13:1-11.
[17] 周姗,杜鹏,郑欣,等.2010年至2012年深圳地区献血者隐匿性乙型肝炎病毒感染的分子病毒学特征.中华传染病杂志,2015,33:150-153.
[18] Zhang Z,Zhang L,Dai Y,et al.Occult hepatitis B virus infection: influence of S protein variants. Virology Journal,2016,13:1-11.
[19] 郑洁,曾爱忠.隐匿性乙肝与肝细胞肝癌关系的研究进展.重庆医科大学学报,2015,40:321-324.
[20] 陈丽萍,赵红,吕蓓,等.HBsAg阴性的HBV感染与肝癌.肝脏,2015,20,408-409.
[21] 刘永振,王杰,陈香梅,等.乙型肝炎病毒再激活研究进展.肝脏,2014, 19:777-781.
[22] 王丽,徐诚,王宇明等.慢性乙型肝炎患者发生HBsAg血清学清除后的长期临床观察.肝脏,2015,20:372-375.
[23] 马源,张玲荣,王博,等.不明原因肝病患者中隐匿性HBV感染的研究.中国医疗前沿,2011,6:5-6.
[24] 赵珍珍,范晓棠,希尔娜依 阿不都黑力力,等.HBsAg阴性、抗-HBs/抗 -HBe/抗-HBc阳性肝硬化病因特点.世界华人消化杂志,2014,31:4844-4848.
[25] 郑洁、曾爱忠.隐匿性乙肝与肝细胞肝癌关系的研究进展.重庆医科大学学报,2015,3:171-173.
[26] 李丽,勾春燕,李晶滢,等.肝炎病毒相关肝内胆管细胞癌的流行病学特点分析92例.世界华人消化杂志,2014,22:3148-3152.
[27] Xiong QF, Zhong YD, Hu ZL. Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy.Acta Clinica Belgica,2015,70:223-225.
[28] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10:1-98.
[29] Xiong QF,Zhong YD,Hu ZL.Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy.Acta Clinica Belgica,2015,70:223-225.
[30] Jang JW, Kim YW, Lee SW, et al. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular-Carcinoma. PLoS ONE,2015,10:1-12.
[31] Konstantinou D,Deutsch M.The spectrum of HBV/HCV coinfection: epidemiology,clinical,characteristics,viralinter- actions and management. Ann Gastroenterol,2015,28:221-228.
[32] 中华医学会肝病学分会,中华医学会感染病学分会.慢性丙型肝炎防治指南(2015年版). 肝脏,2015, 20: 933-949.
[33] Dong PL,Zhang X,Zhao WM,et al.HBsAg Loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: acase report. J Infect Chemother,2013,19:1188-1192.
[34] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).中国肝脏病杂志(电子版),2015,7:1-18. |
